OraLiva, Inc. is on the cusp of launching an AI-powered cytology “lab-in-a-kit” platform aimed at transforming early oral cancer diagnosis. The system captures cells via a non-invasive brush biopsy, runs them through OraLiva’s proprietary AI engine and compares the sample against a deep clinical dataset to detect early dysplasia or malignancy with high precision.
